These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 19563206)

  • 21. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Apr; 71(71):19193-4. PubMed ID: 16612859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Food and Drug Administration proposed testing guidelines for developmental toxicity studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
    Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
    Regul Toxicol Pharmacol; 1999 Aug; 30(1):39-44. PubMed ID: 10464045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the feasibility of using the DBS technique for metabolite radioprofiling.
    Wang L; Zeng Z; Emmons G
    Bioanalysis; 2010 Aug; 2(8):1365-71. PubMed ID: 21083337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety evaluation to support First-In-Man investigations II: toxicology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
    Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
    Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
    Tsuda M; Ohno Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Food and Drug Administration proposed testing guidelines for reproduction studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
    Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
    Regul Toxicol Pharmacol; 1999 Aug; 30(1):29-38. PubMed ID: 10464044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues in the safety testing of metabolites.
    Gross G; Wilson I
    Future Med Chem; 2009 Nov; 1(8):1381-90. PubMed ID: 21426053
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
    Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ
    Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.